

PROGRAMME



# MODERNISING THE LANDSCAPE OF CANCER CARE



BEAUMONT RCSI  
CANCER CENTRE

# PROGRAMME

09:00	<b>Delegate registration opens</b>
09:45	<b>Welcome address</b> <i>Delivered by Anne Coyle</i> CEO, Beaumont Hospital
<b>SESSION ONE</b>	
<b>CHAIR</b> <b>Dr Damir Vareslija</b> Senior Lecturer and Principal Investigator, School of Pharmacy and Biomolecular Sciences, RCSI	
10.00	<b>Supporting adherence to treatment in breast cancer</b> <i>Keynote delivered by Professor Linda Sharp</i> Professor of Cancer Epidemiology, University of Newcastle
10.30	<b>Advancing oesophago-gastric cancer surgery - Beaumont's robotic oesophagectomy program</b> <i>Delivered by Professor Will Robb</i> Consultant General and Oesophago-Gastric Surgeon, Robotic Surgery, Beaumont RCSI Cancer Centre
10.50	<b>Digital pathology, from pigeons to pixels</b> <i>Delivered by Professor Brendan Doyle</i> Consultant Pathologist, Molecular and Digital Pathology, Beaumont RCSI Cancer Centre Digital Pathology
11.10	<b>Panel discussion with all speakers</b> <i>Chaired by Dr Damir Vareslija</i> Senior Lecturer and Principal Investigator, School of Pharmacy and Biomolecular Sciences, RCSI
11.20	Coffee and poster viewing

# PROGRAMME

## SESSION TWO

### CHAIR

**Professor Deirdre Duke**, Consultant Radiologist, Beaumont Hospital

11.50	<b>What's new in radiation oncology – from SABR to protons and beyond!</b> <i>Delivered by Professor Gerry Hanna</i> Marie Curie Chair of Clinical Oncology, TCD and Consultant in Radiation Oncology, St Luke's Radiation Oncology Network
12.10	<b>Clinical application of AI in radiation oncology: Are we ready?</b> <i>Delivered by Ciaran Malone</i> SLICR Research Fellow & Senior Medical Physicist
12.30	<b>Role of AI and digital health in shaping future of cancer care</b> <i>Delivered by Dr Sudipto Das</i> Vice-Dean for AI and Digital, Connected Health
12.50	<b>Panel discussion with all speakers</b> <i>Chaired by Professor Deirdre Duke</i> , Consultant Radiologist, Beaumont Hospital
13.00	Lunch and Poster Viewing

## SESSION THREE

### CHAIR

**Professor Patrick G. Morris MD, FRCPI**  
Medical Director, Beaumont RCSI Cancer Centre

14.00	<b>Psycho-Oncology in Ireland, working together to produce better outcomes for patients.</b> <i>Delivered by Dr Helen Greally</i> Director of Psychology and Support Services, Cancer Care West, Galway
14.20	<b>Public perspectives on challenging health topics – The IPPOSI citizens' jury experience</b> <i>Delivered by Laura Kavanagh</i> Research & Advocacy Manager at IPPOSI (Irish Platform for Patient Organisations, Science and Industry)
14.40	<b>Cancer patient partnership in practice</b> <i>Delivered by Claire Buckley</i> Patient Representative Board Member - Beaumont RCSI Cancer Centre
14.50	<b>Panel discussion with all speakers</b> <i>Chaired by Professor Patrick G. Morris MD, FRCPI</i> , Medical Director, Beaumont RCSI Cancer Centre
15.00	<b>Deploying AI in healthcare: Dream, delay, or deployment?</b> <i>Keynote delivered by Professor Arsela Prelaj</i> Fondazione IRCCS Istituto Nazionale Tumori, & Dipartimento di Elettronica, Informazione e Bioingegneria di Milano

## SPEAKERS



### Professor Linda Sharp

Linda Sharp joined Newcastle University in 2015 as Professor of Cancer Epidemiology. Prior to that, she was Research Lead at the National Cancer Registry Ireland for a decade. Having started her professional career as a statistician at the Scottish Cancer Registry, she now has 30 years experience in cancer research.

Over the past 15-20 years, Linda has become known for her expertise in cancer survivorship, having developed a groundbreaking programme of work at NCRI investigating the experiences of cancer patients and their families.

Much of her current research now focusses on the rigorous development and testing of interventions to support survivors and caregivers. She has a specific interest in cancer treatment utilisation and adherence. Her SWEET research programme brings these interests together by developing and testing an intervention to support adherence to endocrine therapy and CDK4/6 inhibitors in women with breast cancer.

Over the course of her career, Linda has published more than 400 peer reviewed papers, co-authored more than 20 official reports (including HTAs and clinical guidelines) and secured more than £45 million in research funding.

## SPEAKERS



### Professor Brendan Doyle

Brendan studied medicine in Trinity College Dublin, where he graduated as a scholar of the College. He did his postgraduate training in Pathology in Dublin, Boston and Glasgow, where he completed a PhD in Molecular Pathology and Cancer Studies. He worked as a lecturer in Trinity College before taking Consultant roles in St. James's Hospital and subsequently Beaumont Hospital in Dublin where he continues to practice as a Consultant Pathologist. He was appointed Associate Professor in the Department of Pathology, RCSI University of Medicine and Health Science in 2023.

Brendan is the clinical lead for molecular diagnostics in the Beaumont/RCSI cancer centre, which offers molecular diagnostic services on a regional and national basis. Brendan has authored numerous papers and a book chapter in the field of molecular pathology. He pursues a program of late-stage translational research leveraging tumour genomics to maximise access to clinical trials and novel therapeutics for cancer patients.

## SPEAKERS



### Professor Gerry Hanna

Professor Gerry Hanna is the Marie Curie Chair of Clinical Oncology at Trinity College Dublin and a Consultant in Radiation Oncology at the St Lukes Radiation Oncology Network within the Trinity St James Cancer Institute. Gerry also holds honorary appointments at the University of Melbourne, and Queen's University Belfast.

His Research interests include the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy.

Prof Hanna is the Vice-Clinical Lead of Cancer Trials Ireland, Chief Investigator of the Peter Mac ACRF Radiation Immuno-oncology Program and the International Atomic Energy Agency's "PERTAIN" study. He is the former chief investigator and current TMG member of the CRUK funded CONCORDE study. Gerry is also a TMG member for the UK's HALT, SARON, CONFIRM and ISOTOXIC IMRT studies and continues to provide research support to Belfast Trust.

## SPEAKERS



### Ciaran Malone

Currently, Ciaran is undertaking a two-year SLICR Research Fellowship at St. Luke's, focusing on AI and adaptation in Radiation Oncology. He continues to work a Senior Medical Physicist for the past 11 years in the St. Luke's Radiation Oncology Network, Dublin. He is also a guest lecturer at University College Dublin's School of Physics, contributing to the M.Sc. in Medical Physics curriculum. Additionally, Ciaran sits on the National Cancer Control Programme's AI in Radiation Oncology working group, collaborating with multidisciplinary experts to integrate AI into practice and foster collaboration across radiation oncology centres in Ireland.

## SPEAKERS



### Dr Sudipto Das

Dr Sudipto Das is a senior lecturer in the School of Pharmacy and biomolecular sciences and also the Vice Dean for AI and digital/connected health, Royal College of Surgeons in Ireland (RCSI). Dr Das is the lead of the “Epigenetics of Gastrointestinal Diseases” research group, which focusses on applying multi-omic sequencing combined with functional epigenomic approaches to identify epigenetic altered loci which can act as novel biomarkers of disease progression as well as putative therapeutic targets to impede this process in diseases such as colorectal cancer, head and neck cancer and inflammatory bowel diseases. His group consisting of post-doctoral researchers, research lecturers, PhD students and MD students, collaborates widely with global institutes such as VIB, K.U., Leuven Belgium and Memorial Sloan Kettering Cancer center, USA.

Sudipto has also led development and implementation of cutting edge post-graduate programmes including M.Sc - Technologies & Analytics in Precision medicine, which includes modules on concepts and application of connected health as well as AI in healthcare. Previously, as deputy head of school of post-graduate studies, Sudipto has led doctoral programmes such as Professional Doctorate programme as well as intercalated M.Sc by Research programmes at RCSI.

## SPEAKERS



### Dr Helen Greally

Helen Greally was National Clinical Lead in Psycho-Oncology at the National Cancer Control Programme, from 2018 to 2024, where her role has focused on the development of an integrated patient pathway for cancer patients and their families. She has been the lead author on three significant publications that shape national service delivery – a national model of care for psycho-oncology with adults, a national model of care for psycho-oncology with children, adolescents and young adults (CAYA), and best practice guidelines for community cancer support centres. Helen devoted great energy to developing evidence-based national models of care to ensure that Psycho-Oncology care is equitable, accessible, and effective. There is no doubt that Helen has influenced the psycho-oncology services for people living in Ireland.

She received the Noemi Fisman Award for Lifetime Clinical Excellence from the International Psycho-Oncology Society in September of 2024.

Helen is also Director of Psychology and Psychosocial supports at Cancer Care West, based in Galway city, where her role has been primarily to advance and consolidate the delivery of Psycho-Oncology and support services to cancer patients and their families in the west of Ireland in line with best international practice.

## SPEAKERS



### Laura Kavanagh

Laura Kavanagh is the Research and Advocacy Manager at IPPOSI, where she focuses on placing the patient voice at the centre of health policy, care, research, and innovation. As Co-Chair of the HSE Patient and Service User Forum, Laura has supported the co-design of partnership structures for Ireland's new health regions. At IPPOSI she has organised three citizens' juries, including the 2024 jury that focused on exploring the use of AI in healthcare in Ireland.

With a background in human rights and public participation, Laura has previously worked with intergovernmental organisations, including the UN, OSCE, and the Council of Europe, as well as with local government structures in London and with European projects such as EUPATI.

## SPEAKERS



### Claire Buckley

Claire Buckley joined the board of the Beaumont RCSI Cancer Centre as a patient representative in 2021, having been treated for breast cancer in 2019. She serves as a liaison between the Cancer Patient Partnership Working Group and the Board, ensuring that the patient voice remains central to the Board's planning and decision-making.

Claire is passionate about the importance of patient advocacy, clinical trial participation, and research aimed at improving patient experiences and health outcomes.

In her professional career, Claire has worked as a Human Resources professional for over 30 years in the IT and public sectors.

## SPEAKERS



### Professor Arsela Prelaj

She is a Consultant Medical Oncologist specializing in thoracic malignancies at the Thoracic Unit of Istituto Nazionale Tumori di Milano in Italy since 2018. She completed her residency in Medical Oncology at Sapienza University, Policlinico Umberto I Hospital in Rome, Italy. During her training, she was awarded the ESMO Clinical Unit Visit in 2017 and spent time at The Christie Hospital in Manchester in the Lung Cancer Division. Over the past seven years, her research has primarily focused on thoracic malignancies, particularly non-small cell lung cancer (NSCLC) and translational immunotherapy.

Professor Arsela Prelaj recently earned a Ph.D. in Bioengineering and Artificial Intelligence from Politecnico di Milano. She serves as the principal investigator for multiple international clinical trials and is actively involved in coordinating various national and international grant applications in the field of thoracic malignancies and immunotherapy. As the head of the AI-ON-Lab (Artificial Intelligence for Oncology Lab) at Istituto Nazionale Tumori di Milano, she is responsible for leading research and development in the application of AI in oncology. Furthermore, she has been appointed as the Responsible for INT's Research Line 4 program, which focuses on big data, clinical research, healthcare, and outcome research.

Professor Arsela Prelaj is an esteemed member of the ESMO Working Group on Real-World Data and Digital Health, and her expertise in AI has led to collaborations with ESMO starting in 2021. She is leading many EU and National projects: I3LUNG, a 10-million project, APOLLO 11, BuonMarrow (4-million, Bone Marrow-on-Chip). She is PI of the SHAIPEP EU project focus on health data body access. Finally, she is the President of the new founded European Interdisciplinary Society of AI in Cancer Research (ESAC)

She is an ESMO, ASCO, AACR, IASLC and AIOM member and faculty member at many congresses on AI.

## SPONSORS

AstraZeneca 

 Bristol Myers Squibb™

**EXACT  
SCIENCES**

 **GILEAD**

**GSK**

 **MSD**

 **NOVARTIS**



**AMGEN**®





# ABSTRACTS

- 1. Reversal of epigenetic dysregulation in breast cancer brain metastasis via HDAC1/2 inhibition**  
Lara Luzietti, Gabriela Gomez, Stephen Shovlin, Aoibheann Dowd, Petra Jagust, Leonie Young, Damir Vareslija
- 2. NFp10a-Luc2: A clinically relevant, syngeneic model for evaluating TME-targeted therapies in mesenchymal glioblastoma**  
Kieron White, James Clerkin, Liam P. Shiels, Kieron Sweeney, Mohannad Dabour, Alice C. O'Farrell, Maite Verreault, Thomas Van Brussel, Ingrid Arijs, Suzanne Murphy, Evin Haworth, Christopher Van Hessche, Gautam Shankar, Colum Connolly, Joana Beyer, Patrick Dicker, Stephen G. Maher, Laure Marignol, David O'Brien, Diether Lambrechts, Jochen H.M. Prehn, Ahmed Ibdiah, Frederik de Smet, Kate Connor, and Annette T. Byrne
- 3. Uncovering biomarkers of breast cancer cell reawakening**  
Ciara Walsh, Jacob Donnelly, Stephen Madden and Jean McBryan
- 4. Novel RGD-based peptides disrupt JAM-A mediated signaling in high risk multiple myeloma**  
N McAuley, L Donnelly, D Bong, R McAvera, J Fay, L Hudson, M Brennan, M Devocelle, SV Glavey, AM Hopkins
- 5. Biological and molecular characterization of novel glioblastoma TME subtypes reveals distinct therapeutic vulnerabilities**  
Mohannad Dabbour, Kieron White, Aleksandr Kalmykov, Alexander Kel , Heiko Dussmann, Kieron Sweeney, Jochen HM Prehn, Annette T. Byrne
- 6. Metabolic perturbations Induced by HDAC6 inhibition generate sensitivities to amino acid depletions in multiple myeloma models**  
Matthew Hiller
- 7. Metabolic and apoptotic dependencies in multiple myeloma: Insights into BCL-2 dependency**  
Ludovica Di Martino, Stephanie Gilmore, Yu Wang, Siobhan Glavey, Triona Ní Chonghaile
- 8. Prospective evaluation of clinical benefit and micro-costing of plasma-first for patients with newly diagnosed advanced non-small cell lung cancer**  
David O Reilly, Tony O Grady, Conor Hayes, Laura Piggott, Ruairi Keane, Orla Fitzpatrick, Michael Conroy, Nicholas Kruseman Aretz, David Synnott, Rachel Dillon, Daniel J. Ryan, Emmet O'Brien, Ross Morgan, Oscar Breathnach, Liam Grogan, Patrick Morris, Megan Greally, Adrian Murphy , Ian Counihan, Cliona Ryan, Helen Barrett, Ann-Marie O'Shea, Sinead Cuffe, Grzegorz Korpany, Lisa Prior, Martin Barr, Stephen Finn, Cathal O'Brien, Sarah McCarron, Rob Cummins, Sinead Toomey, Bryan Hennessy, Jan Sorensen, Kathleen Bennett, Parthiban Nadarajan, Brendan Doyle, Jarushka Naidoo
- 9. Global proteomic assessment of a novel HDAC6 inhibitor and PROTAC in multiple myeloma.**  
Cian D'Arcy, Daniel Alencar Rodrigues, Kieran Wynn, Andrew Roe and Triona Ní Chonghaile

# ABSTRACTS

**10. Epigenetic modifier GSK-J4 enhances sensitivity to Venetoclax in multiple myeloma**

Stephanie Gilmore,  
Lyndsey Flanagan, Aisling Coughlan, Ludovica Di Martino, Matthew Hiller, Siobhan Glavey, Triona Ní Chonghaile

**11. Assessing the activity of a commercially available BCL-XL targeting PROTAC in multiple myeloma**

Keelan Farnan, Joshua McClean, Karina Chan, Stephanie Gilmore, Darren Griffith, Triona Ní Chonghaile

**12. Characterizing the TME-Low subtype of glioblastoma for precision therapy**

Suzanne Murphy, Mohannad Dabour, Kieron White, Frank Lincoln, Colum Connolly, Liam Shiels, Jochen HM. Prehn, David O'Brien, Annette T. Byrne, Kate Connor

**13. Combined BRCA mutation and homologous recombinant deficiency testing broadens therapeutic scope in high grade ovarian cancer**

Dr Gráinne O'Keefe, Etáin Daly, Prof Brendan Doyle

**14. Physical activity for people living with a cancer diagnosis: Oncology staff and patient perceptions**

Barry, Niamh; Jones, Leah; Liutec, Alexandra; McDermott, Caoimhe

**15. Audit of patient survivorship and patient resource needs**

Dr Victoria Lunt- Principal Psychologist, Kimberly Kiyui – Assistant Psychologist, Noreen Andersen-Clinical Nurse Specialist, Dr Maurice Clancy- Consultant Psychiatrist, Dr Jennifer Fennell- Senior Psychologist, Dr Ruth Stewart- Senior Psychologist, Sarah Murran- Senior Medical Social Worker, Aoife McGovern- Senior Medical Social Work

**16. Using co-operative inquiry to examine gaps in rehabilitation access after a brain tumour diagnosis and treatment ("BRAIN-RESTORE")**

N Kavanagh, B O'Donovan, S Donnelly, E Cowie, K Fowler , F Horgan, K Bennett , A Malone

**17. Exploring Social Prescribing as a support service for men with prostate cancer: A mixed methods study**

Deirdre Connolly, Hayley Connolly, Peter Lonergan, Louise McLoughlin, Anna Loughlin, Moya Cunningham, Pierre Thirion, Claudia Carvajal, Sanjines Kay, Leonard Rustom Manecksha, Rowan Casey

**18. Development of a psycho-oncology support calendar**

Jennifer Fannell, Cooper, V Lunt, K Farcas

**19. Optimising the effective management of depression among patients with cancer (ENHANCE) in Ireland: Findings from a systematic review of depression interventions and a qualitative stakeholder study.**

Maria M Pertl, Rahela Beghean, Sonya Collier, Emer Guinan, Garret Monahan, Katie Verling, Emma Wallace, Aisling Walsh, Arun Ghoshal, Emer Galvin, Frank Doyle

**20. A retrospective audit of the acute haematology oncology telephone triage service 2021-2025**

MarieClare McEvoy, Laura French, Linda Treanor

# ABSTRACTS

21. **Comparative effectiveness of digital breast tomosynthesis and mammography in breast cancer detection among women over 40: A systematic review**  
Dr. Yumna Salman, RCSI  
Bahrain
22. **Mapping the landscape of oral cancers: A systematic review of patient outcomes in adjuvant management strategies used in oral squamous cell carcinoma**  
Hannah Maguire
23. **Thyroid malignancy rate in thyroid nodules**  
Merah Al Busaidy, Kevin Burke Diarmuid Smith, Mark Sherlock, Michael W O'Reilly, Krzysztof Wanic, Paul O'Neill, Arnold Hill, Martina Morrin, Ruth Dunne, John Cunningham, Cliona Ryan, Amar Agha
24. **Minimally invasive strategies for management of T3b renal tumours**  
Caroline Kelly, Paul Ryan, Asyraf Maarof, Ati Ferede, Ijaz Cheema, Richard Power, Doug Mullholland, Usman Haroon
25. **Introduction of a radiotherapy staff lead MRI planning service in the St. Luke's radiation oncology network**  
Margaret Tynan
26. **Ensuring fair access to colorectal cancer screening**  
Éanán Finnegan, Derek Corrigan, Tsukushi Kayima, Michelle O'Neill Daniela Rohde, Susan Spillane, Máirín Ryan
27. **Implementation trial of prostate cancer screening using a home PSA test and follow up MRI**  
Gillian Horgan, Riya Negi, William Watson, Patrick Murray, Brenda Molloy, Patricia Fitzpatrick, Paul Sweeney, Alan Smith, David Galvin
28. **Scoping review on the use of transactional data for early diagnosis (TRADED-ScR)**  
Kurdo Araz, Benjamin M Jacob, James Flanagan, Patrick Redmond
29. **Recruitment strategies for lung cancer screening: An umbrella review of effectiveness in low-participation subcohorts**  
B Cushing, X Low, B Jacob, S McGlynn, P Redmond.
30. **An audit of compliance with the local guidelines in Midland Regional Hospital Tullamore (MRHT) in serum free light chains (SFLCs) testing in multiple myeloma patients' disease monitoring (Cycles 1 & 2)**  
Ahmed Abdul Hafeiz
31. **Pilot phase of IPCOR - A digital clinical quality registry & biorepository to advance prostate cancer care in Ireland**  
Wasfa Farooq, Linh Hoang, Noa Gordon, William Watson, Sharon Glynn, David Galvin
32. **Clinical trials webpage update project**  
Hebatalla Ismail, Caitriona Higgins, Patrick Morris
33. **Visualising our cancer patient pathway - Implementing digital cancer dashboards**  
Claire Noonan, Alan Carter, Amanda McDonnell, Blathnaid O'Sullivan, Caitriona Higgins, Eithne Downey, Paul Cully, Stephen Boylan, Tony McNamara, Yvonne O'Hannigan, Patrick Morris



# RCSI

**RCSI** Royal College of Surgeons in Ireland  
123 St Stephen's Green, Dublin 2  
Tel: +353 1 402 2100  
Email: [events@rcsi.com](mailto:events@rcsi.com)  
[rcsi.com](http://rcsi.com)



**BEAUMONT RCSI  
CANCER CENTRE**

Beaumont RCSI Cancer Centre  
Beaumont Hospital Campus,  
Beaumont Road, Dublin 9.  
Tel: +353 1 809 3000

## **CONFERENCE GUEST WIFI**

Select RCSI-GUEST

Log in using the following details:

Password: RC\$1guest